Igene Biotechnology, Inc. (IGNE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Igene Biotechnology, Inc. (IGNE) trades at $0.00 with AI Score 47/100 (Grade C). Igene Biotechnology, Inc. specializes in the development and commercialization of specialty ingredients for human and animal nutrition, focusing on natural astaxanthin. Market cap: $15,654, Sector: Basic materials.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for IGNE: IGNE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IGNE against Basic Materials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IGNE: the 1 perspectives are evenly split.
How is this calculated? →Igene Biotechnology, Inc. (IGNE) Materials & Commodity Exposure
Igene Biotechnology, Inc. is a leader in the production of natural astaxanthin, catering to the nutritional needs of both human and animal markets, while offering research and development services in microbial strain improvement.
What Is the Investment Thesis for IGNE?
Igene Biotechnology, Inc. operates within a niche market that is experiencing increasing demand for natural ingredients in both human and animal nutrition sectors. The company's focus on natural astaxanthin provides a unique value proposition, as this ingredient is essential for enhancing the color and nutritional value of farmed fish, a growing segment within the aquaculture industry. With a gross margin of 25.7%, Igene demonstrates its ability to maintain profitability despite challenges, while its negative profit margin of -3.6% indicates potential areas for operational improvement. The global astaxanthin market is projected to grow significantly, driven by rising consumer awareness of health benefits associated with natural pigments. Furthermore, Igene's capabilities in microbial strain improvement and fermentation process development position it to capitalize on emerging trends in the nutraceutical space. However, investors should remain cautious of the company's current P/E ratio of -0.11, which reflects its ongoing financial challenges and the need for strategic initiatives to return to profitability.
Based on FMP financials and quantitative analysis
IGNE Key Highlights
- Market Cap: $0.00B, indicating a currently unvalued position in the market.
- P/E Ratio: -0.11, highlighting ongoing financial challenges.
- Profit Margin: -3.6%, indicating potential areas for operational improvement.
- Gross Margin: 25.7%, showcasing the company's ability to maintain profitability in its niche.
- Beta: -23.34, suggesting extreme volatility in stock performance.
Who Are IGNE's Competitors?
IGNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MBII Marrone Bio Innovations, Inc. | $0.80 | -20.19% | 68 | |
| AGRZ Agroz Inc. | $0.39 | -2.16% | $8.45M | 61 |
| KNGW Kenongwo Group US, Inc. | $0.32 | +0.00% | $32.60M | 59 |
| BHST BioHarvest Sciences Inc. | $3.00 | +4.53% | $51.98M | 59 |
| FTZZF Canadian Phosphate Limited | $0.16 | +2185.71% | $87.59M | 48 |
| FMC FMC Corporation | $11.46 | +0.93% | $1.43B | 48 |
| CTA-PB E. I. du Pont de Nemours and Company | $65.95 | -0.13% | $57.31B | 48 |
| MBCF Itafos Inc. | $2.10 | -4.26% | $405.79M | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IGNE's Key Strengths?
- Specialized expertise in natural astaxanthin production.
- Established relationships within the nutraceutical and feed industries.
- Strong R&D capabilities for product innovation.
What Are IGNE's Weaknesses?
- Small workforce of 18 employees, limiting operational capacity.
- Negative profit margin indicating financial challenges.
- Dependence on a niche market for revenue.
What Could Drive IGNE Stock Higher?
- Expansion of product offerings in the nutraceutical sector.
- Development of new microbial strains for improved fermentation processes.
- Increased demand for natural astaxanthin in aquaculture markets.
What Are the Key Risks for IGNE?
- Financial-distress signal — its Altman Z-Score of -22.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory changes impacting the agricultural inputs sector.
- Competition from other companies producing natural pigments.
- Financial instability due to negative profit margins.
What Are the Growth Opportunities for IGNE?
- Growth opportunity 1: The global astaxanthin market is projected to reach $1.5 billion by 2027, growing at a CAGR of 15%. Igene's established expertise in natural astaxanthin production positions it to capture a significant share of this expanding market. By enhancing its production capabilities and marketing efforts, Igene can leverage this growth trend to increase revenue and market presence.
- Growth opportunity 2: The nutraceutical sector is increasingly leaning towards natural ingredients, with a projected market size of $300 billion by 2025. Igene's ability to supply high-quality natural ingredients aligns with this trend, providing substantial growth potential. By expanding its product offerings and targeting health-conscious consumers, Igene can tap into this lucrative market.
- Growth opportunity 3: The increasing awareness of the benefits of natural pigments in aquaculture presents an opportunity for Igene to expand its client base among fish farmers. With the global aquaculture market expected to grow at a CAGR of 5.3% through 2027, Igene can enhance its sales by promoting the advantages of its astaxanthin products to fish farming operations.
- Growth opportunity 4: Igene's research and development capabilities in microbial strain improvement can lead to innovative product offerings, enhancing its competitive advantage. The global market for microbial products in agriculture is anticipated to grow significantly, allowing Igene to diversify its revenue streams through new product development.
- Growth opportunity 5: The demand for analytical chemistry services is on the rise, particularly in food safety and quality assurance. By expanding its analytical services to include more comprehensive testing for carotenoids and other nutrients, Igene can increase its service offerings and attract a broader clientele within the food and feed industries.
What Opportunities Does IGNE Have?
- Growing global demand for natural ingredients in nutrition.
- Expansion potential in the aquaculture market.
- Increasing interest in microbial products for agriculture.
What Threats Does IGNE Face?
- Intense competition within the agricultural inputs sector.
- Market volatility affecting ingredient prices.
- Regulatory challenges in food and feed industries.
What Are IGNE's Competitive Advantages?
- Established expertise in natural astaxanthin production.
- Strong R&D capabilities in microbial strain improvement.
- Unique analytical services for carotenoid verification.
What Does IGNE Do?
Founded in 1981, Igene Biotechnology, Inc. has established itself as a pioneering force in the agricultural inputs sector, specializing in the research, development, production, and commercialization of specialty ingredients aimed at enhancing human and animal nutrition. Originally known as IGI Biotechnology, Inc., the company rebranded to its current name in April 1986. Headquartered in Columbia, Maryland, Igene focuses on natural astaxanthin, a critical nutrient that serves as a pigment source for coloring farmed salmon and trout species. Beyond astaxanthin, the company also supplies a range of ingredients and finished products to the nutraceutical and feed industries. Igene's expertise extends to providing research and development services for microbial strain improvement and fermentation process development, scaling operations from shake flasks to pilot plants and commercial-sized fermentors. Additionally, the company offers analytical chemistry services for the identification and quantization of carotenoids in various food and feed products, including the verification of wild versus farm-raised salmonids. With a dedicated workforce of 18 employees, Igene Biotechnology is positioned to leverage its innovative capabilities to meet the growing demand for natural nutritional solutions in an increasingly health-conscious market.
What Products and Services Does IGNE Offer?
- Research and develop specialty ingredients for human and animal nutrition.
- Produce natural astaxanthin for coloring farmed salmon and trout.
- Supply nutraceutical and feed industry products.
- Provide research and development services for microbial strain improvement.
- Offer fermentation process development and scale-up services.
- Deliver analytical chemistry services for carotenoid identification and quantization.
How Does IGNE Make Money?
- Generate revenue through the sale of specialty ingredients and products.
- Offer research and development services to clients in the nutraceutical and feed industries.
- Provide analytical services to verify the quality and source of carotenoids.
What Industry Does IGNE Operate In?
The agricultural inputs industry is witnessing a shift towards natural and sustainable ingredients, driven by consumer demand for healthier food options and environmentally friendly practices. As aquaculture continues to expand globally, the need for natural colorants like astaxanthin is increasing, positioning Igene Biotechnology favorably within this growth trajectory. The global astaxanthin market is expected to reach approximately $1.5 billion by 2027, with a CAGR of around 15%. Igene's focus on research and development further enhances its competitive edge, allowing it to innovate and meet evolving market demands.
Who Are IGNE's Key Customers?
- Aquaculture businesses requiring natural colorants for fish.
- Nutraceutical companies seeking high-quality ingredients.
- Feed manufacturers looking for specialized additives.
How Igene Biotechnology, Inc. Is Valued
Igene Biotechnology, Inc. carries a market capitalization of 16K, placing it in the micro-cap category. Relative to its peer group, IGNE's quantitative score of 47/100 is below the peer average of 59/100.
Company Profile
Igene Biotechnology, Inc. operates in the Agricultural Inputs industry within the Basic Materials sector. It is headquartered in Columbia, US. The company is led by CEO Joseph L. Downs. IGNE has traded publicly since 1995.
ROE 5%Key Financial Metrics
Return on equity for Igene Biotechnology, Inc. stands at 5.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.0%, showing how much profit it generates from its asset base. A current ratio of 2.35 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 1/9Financial Health
Igene Biotechnology, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.97 places it in the distress zone, a signal of elevated financial risk.
IGNE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth trajectory.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to biotechnology and its potential market applications.
- Recent partnerships and collaborations have generated excitement, positioning Igene Biotechnology as a forward-thinking player in the biotech sector.
- Increased media coverage over the last month has raised awareness, leading to a more favorable perception among retail investors.
Bear Case
- Concerns over regulatory hurdles in the biotech space have dampened enthusiasm, with some investors wary of potential delays in product approvals.
- Market sentiment has been mixed, with some community members expressing skepticism about the scalability of Igene's technologies and their commercial viability.
- Recent earnings reports have not met expectations, leading to disappointment and a reevaluation of the company's short-term outlook.
- Overall market volatility has impacted investor sentiment, causing some to adopt a more cautious approach towards biotech stocks, including Igene.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IGNE Latest News
-
Latvia’s President Nominates Kulbergs to Form New Government
Bloomberg · May 16, 2026
IGNE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IGNE.
Price Targets
Wall Street price target analysis for IGNE.
IGNE MoonshotScore
What does this score mean?
The MoonshotScore rates IGNE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Agricultural InputsLeadership: Joseph L. Downs
CEO
Joseph L. Downs has been at the helm of Igene Biotechnology, Inc. for several years, bringing extensive experience in biotechnology and business management. He has a strong background in developing innovative solutions for the agricultural sector, with a focus on enhancing product quality and operational efficiency. His leadership is characterized by a commitment to advancing the company's research and development initiatives.
Track Record: Under Joseph L. Downs' leadership, Igene has made significant strides in refining its production processes and expanding its product offerings. His strategic decisions have positioned the company to better meet the needs of its clients in the nutraceutical and feed industries.
IGNE OTC Market Information
The OTC Other tier refers to stocks that do not meet the criteria for higher tiers like OTCQX or OTCQB, often indicating lower visibility and liquidity. Companies in this tier may have less stringent reporting requirements, which can affect investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Less regulatory oversight compared to stocks listed on major exchanges.
- Potential for lower liquidity, making it difficult to buy or sell shares.
- Higher volatility due to lower trading volumes and investor interest.
- Review recent financial statements and disclosures.
- Assess the company's market position and competitive landscape.
- Evaluate management's track record and strategic vision.
- Investigate any legal or regulatory issues affecting the company.
- Consider the overall market conditions and trends in the agricultural inputs sector.
- Established company history since 1981.
- Focus on R&D and innovation in specialty ingredients.
- Partnerships with clients in the nutraceutical and feed industries.
What Investors Ask About Igene Biotechnology, Inc. (IGNE) — Basic Materials
What does Igene Biotechnology, Inc. do?
Igene Biotechnology, Inc. specializes in the research, development, and commercialization of specialty ingredients for human and animal nutrition. The company is particularly known for its production of natural astaxanthin, which is used as a pigment in farmed salmon and trout. Additionally, Igene provides ingredients and finished products to the nutraceutical and feed industries, along with research and development services for microbial strain improvement and fermentation processes.
How does Igene Biotechnology, Inc. compare to competitors in its industry?
Igene Biotechnology, Inc. operates in a niche market focused on natural astaxanthin, which differentiates it from competitors like AgriFORCE Growing Systems Ltd. and American Green. While these competitors may focus on broader agricultural solutions, Igene's specialized expertise in natural ingredients for nutrition gives it a unique position. Its commitment to research and development further enhances its competitive edge, allowing it to innovate and meet specific market demands effectively.
What are the key financial metrics investors watch for IGNE?
Investors typically focus on several key financial metrics for Igene Biotechnology, Inc., including its P/E ratio, which currently stands at -0.11, indicating ongoing financial challenges. The profit margin of -3.6% suggests that the company is operating at a loss, while the gross margin of 25.7% indicates its ability to maintain profitability in its niche. Monitoring these metrics can provide insights into the company's operational efficiency and financial health.
What are the main risks for IGNE?
Igene Biotechnology, Inc. faces several risks, including potential regulatory changes that could impact the agricultural inputs sector, which may affect its operations and product offerings. Ongoing competition from other companies producing natural pigments poses a threat to market share. Additionally, the company's current negative profit margin indicates financial instability, which could hinder its ability to invest in growth opportunities and innovation.
What are the key factors to evaluate for IGNE?
Igene Biotechnology, Inc. (IGNE) holds an AI score of 47/100 (low). Not financial advice.
How frequently does IGNE data refresh on this page?
IGNE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IGNE's recent stock price performance?
Igene Biotechnology, Inc. (IGNE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in natural astaxanthin production. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IGNE overvalued or undervalued right now?
Valuing Igene Biotechnology, Inc. (IGNE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data may be subject to change as new information becomes available.